We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to ...

Raymond James Financial Inc. purchased a new position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the fourth quarter, ...

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

This supports the company’s belief that improved clinical outcomes can be derived from significant IgG reductions, which ...

With these trends in view, let’s look at the 10 best mid cap biotech stocks to buy.

a professor at KIT’s Institute for Microprocess Engineering (IMVT) in a press release. The production of syngas, a mixture of carbon monoxide (CO) and hydrogen, is a critical step in making ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant ( IMVT – Research Report) yesterday and set a price target of $52.00. The company’s shares closed yesterday at $19.69.

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of $52.00. The company’s shares closed yesterday at $19.69.